Analysts have recommended India’s pharmaceutical sector as a defensive investment option as geopolitical uncertainty and inflation volatility push investors toward industries with stable demand and export diversification.
Drugmakers tend to benefit from relatively inelastic demand for medicines regardless of economic cycles, and many large Indian pharma firms derive significant revenue from regulated markets in Europe and emerging economies. That geographic mix can cushion companies when U.S. market conditions soften, as seen in recent quarterly results from major players.
Sector valuations have reflected this defensive quality during periods of equity market stress linked to the West Asia conflict and foreign investor outflows. Companies with strong generic portfolios and contract manufacturing operations have drawn particular attention from portfolio managers seeking lower-beta exposure.
However, analysts caution that margin pressures, currency movements and regulatory scrutiny in export markets remain ongoing risks. The defensive label applies primarily to established large-cap names with diversified revenue bases rather than the sector uniformly.
Large-cap names such as Sun Pharmaceutical Industries remain core holdings for funds seeking lower volatility during geopolitical stress. Export revenue diversification into Europe and emerging markets has helped offset periodic U.S. pricing pressure. The Nifty Pharma index declined modestly on May 22 despite the broader market rebound led by financial stocks.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.business-standard.com/markets